164 related articles for article (PubMed ID: 36951406)
1. Key stakeholders' perspectives on providing oral pre-exposure prophylaxis as HIV-prevention standard of care in clinical trials in South Africa.
Beesham I; Milford C; Joseph Davey DL; Smit J; Mansoor LE; Beksinska M
Afr J AIDS Res; 2023 Apr; 22(1):18-26. PubMed ID: 36951406
[No Abstract] [Full Text] [Related]
2. Post-trial access to and use of pre-exposure prophylaxis in Durban, South Africa.
Beesham I; Milford C; Smit J; Joseph Davey DL; Baeten JM; Heffron R; Beksinska M; Mansoor LE
BMC Public Health; 2023 Jun; 23(1):1210. PubMed ID: 37349816
[TBL] [Abstract][Full Text] [Related]
3. Exploring the Use of Oral Pre-exposure Prophylaxis (PrEP) Among Women from Durban, South Africa as Part of the HIV Prevention Package in a Clinical Trial.
Beesham I; Heffron R; Evans S; Baeten JM; Smit J; Beksinska M; Mansoor LE
AIDS Behav; 2021 Apr; 25(4):1112-1119. PubMed ID: 33106996
[TBL] [Abstract][Full Text] [Related]
4. Integrating oral PrEP delivery among African women in a large HIV endpoint-driven clinical trial.
Beesham I; Welch JD; Heffron R; Pleaner M; Kidoguchi L; Palanee-Phillips T; Ahmed K; Baron D; Bukusi EA; Louw C; Mastro TD; Smit J; Batting JR; Malahleha M; Bailey VC; Beksinska M; Donnell D; Baeten JM;
J Int AIDS Soc; 2020 May; 23(5):e25491. PubMed ID: 32396700
[TBL] [Abstract][Full Text] [Related]
5. A qualitative study to explore daily versus on-demand oral pre-exposure prophylaxis (PrEP) in young people from South Africa, Uganda and Zimbabwe.
Dietrich JJ; Ahmed N; Tshabalala G; Wu M; Mulaudzi M; Hornschuh S; Atujuna M; Muhumuza R; Ssemata AS; Stranix-Chibanda L; Nematadzira T; Bekker LG; Martinson N; Seeley J; Fox J
PLoS One; 2023; 18(6):e0287627. PubMed ID: 37384792
[TBL] [Abstract][Full Text] [Related]
6. Daily Oral Pre-exposure Prophylaxis (PrEP) Continuation Among Women from Durban, South Africa, Who Initiated PrEP as Standard of Care for HIV Prevention in a Clinical Trial.
Beesham I; Joseph Davey DL; Beksinska M; Bosman S; Smit J; Mansoor LE
AIDS Behav; 2022 Aug; 26(8):2623-2631. PubMed ID: 35122575
[TBL] [Abstract][Full Text] [Related]
7. Experiences of oral pre-exposure prophylaxis use among heterosexual men accessing sexual and reproductive health services in South Africa: a qualitative study.
Cholo FA; Dada S; Martin CE; Mullick S
J Int AIDS Soc; 2024 May; 27(5):e26249. PubMed ID: 38695102
[TBL] [Abstract][Full Text] [Related]
8. Motivations for pre-exposure prophylaxis uptake and decline in an HIV-hyperendemic setting: findings from a qualitative implementation study in Lesotho.
Chebet JJ; McMahon SA; Tarumbiswa T; Hlalele H; Maponga C; Mandara E; Ernst K; Alaofe H; Baernighausen T; Ehiri JE; Geldsetzer P; Nichter M
AIDS Res Ther; 2023 Jul; 20(1):43. PubMed ID: 37415180
[TBL] [Abstract][Full Text] [Related]
9. "Since both of us are using antiretrovirals, we have been supportive to each other": facilitators and barriers of pre-exposure prophylaxis use in heterosexual HIV serodiscordant couples in Kisumu, Kenya.
Patel RC; Stanford-Moore G; Odoyo J; Pyra M; Wakhungu I; Anand K; Bukusi EA; Baeten JM; Brown JM
J Int AIDS Soc; 2016; 19(1):21134. PubMed ID: 27964776
[TBL] [Abstract][Full Text] [Related]
10. Factors influencing the uptake of a mono-PrEP implant for the prevention of HIV: Males' perspectives from three South African provinces.
Mthimkhulu N; Chidumwa G; Kutywayo A; Mataboge P; Martin CE; Kwatsha K; Makalela N; Mazibuko M; Butler V; Mullick S
PLoS One; 2024; 19(1):e0296341. PubMed ID: 38166044
[TBL] [Abstract][Full Text] [Related]
11. Prospective study of oral pre-exposure prophylaxis initiation and adherence among young women in KwaZulu-Natal, South Africa.
Mansoor LE; Lewis L; Naicker CL; Harkoo I; Dawood H; Naidoo K; Gengiah TN; Samsunder N; Beesham I; Abdool Karim SS; Abdool Karim Q
J Int AIDS Soc; 2022 Jul; 25(7):e25957. PubMed ID: 35785472
[TBL] [Abstract][Full Text] [Related]
12. Stigma in the health clinic and implications for PrEP access and use by adolescent girls and young women: conflicting perspectives in South Africa.
Nyblade L; Ndirangu JW; Speizer IS; Browne FA; Bonner CP; Minnis A; Kline TL; Ahmed K; Howard BN; Cox EN; Rinderle A; Wechsberg WM
BMC Public Health; 2022 Oct; 22(1):1916. PubMed ID: 36242000
[TBL] [Abstract][Full Text] [Related]
13. Barriers and facilitators to pre-exposure prophylaxis (PrEP) eligibility screening and ongoing HIV testing among target populations in Bondo and Rarieda, Kenya: results of a consultation with community stakeholders.
Mack N; Odhiambo J; Wong CM; Agot K
BMC Health Serv Res; 2014 May; 14():231. PubMed ID: 24886646
[TBL] [Abstract][Full Text] [Related]
14. Exploring Perceived Barriers and Facilitators of PrEP Uptake among Young People in Uganda, Zimbabwe, and South Africa.
Muhumuza R; Ssemata AS; Kakande A; Ahmed N; Atujuna M; Nomvuyo M; Bekker LG; Dietrich JJ; Tshabalala G; Hornschuh S; Maluadzi M; Chibanda-Stranix L; Nematadzira T; Weiss HA; Nash S; Fox J; Seeley J
Arch Sex Behav; 2021 May; 50(4):1729-1742. PubMed ID: 33954824
[TBL] [Abstract][Full Text] [Related]
15. Barriers and facilitators to pre-exposure prophylaxis uptake among male sex workers in Mexico: an application of the RE-AIM framework.
Kadiamada-Ibarra H; Hawley NL; Sosa-Rubí SG; Wilson-Barthes M; Franco RR; Galárraga O
BMC Public Health; 2021 Nov; 21(1):2174. PubMed ID: 34837988
[TBL] [Abstract][Full Text] [Related]
16. Uptake of and adherence to oral pre-exposure prophylaxis among adolescent girls and young women at high risk of HIV-infection in Kampala, Uganda: A qualitative study of experiences, facilitators and barriers.
Kayesu I; Mayanja Y; Nakirijja C; Machira YW; Price M; Seeley J; Siu G
BMC Womens Health; 2022 Nov; 22(1):440. PubMed ID: 36357920
[TBL] [Abstract][Full Text] [Related]
17. The influence of HIV-related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study.
Velloza J; Khoza N; Scorgie F; Chitukuta M; Mutero P; Mutiti K; Mangxilana N; Nobula L; Bulterys MA; Atujuna M; Hosek S; Heffron R; Bekker LG; Mgodi N; Chirenje M; Celum C; Delany-Moretlwe S;
J Int AIDS Soc; 2020 Mar; 23(3):e25463. PubMed ID: 32144874
[TBL] [Abstract][Full Text] [Related]
18. Brief Report: Quantifiable Plasma Tenofovir Among South African Women Using Daily Oral Pre-exposure Prophylaxis During the ECHO Trial.
Beesham I; Mansoor LE; Joseph Davey DL; Palanee-Phillips T; Smit J; Ahmed K; Selepe P; Louw C; Singata-Madliki M; Kotze P; Heffron R; Parikh UM; Wiesner L; Rees H; Baeten JM; Beksinska M
J Acquir Immune Defic Syndr; 2022 Sep; 91(1):26-30. PubMed ID: 35972853
[TBL] [Abstract][Full Text] [Related]
19. Experiences with HPTN 067/ADAPT Study-Provided Open-Label PrEP Among Women in Cape Town: Facilitators and Barriers Within a Mutuality Framework.
Amico KR; Wallace M; Bekker LG; Roux S; Atujuna M; Sebastian E; Dye BJ; Elharrar V; Grant RM
AIDS Behav; 2017 May; 21(5):1361-1375. PubMed ID: 27317411
[TBL] [Abstract][Full Text] [Related]
20. Perceptions of Pre-exposure Prophylaxis (PrEP) for HIV prevention among men living with HIV in the context of reproductive goals in South Africa: a qualitative study.
Ntinga X; Isehunwa OO; Msimango LI; Smith PM; Matthews LT; Van Heerden A
BMC Public Health; 2024 Feb; 24(1):553. PubMed ID: 38389039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
